<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684083/" ref="ordinalpos=467&amp;ncbi_uid=5660033&amp;link_uid=PMC3684083" image-link="/pmc/articles/PMC3684083/figure/F4/" class="imagepopup">Fig. 4. Overview of common signal <span class="highlight" style="background-color:">pathway</span> activation in GEP-NENs.  From: EGFR/TGF? and TGF?/CTGF <span class="highlight" style="background-color:">Signaling</span> in Neuroendocrine Neoplasia: Theoretical Therapeutic Targets. </a></div><br /><div class="p4l_captionBody">The signaling pathways activated either directly or due to cross-activation is MAPK and AKT/mTOR signaling. All ligands signal via these pathways to positively regulate proliferation and metastasis. Separately, an event that only occurs in a subset of GEP-NENs (Small-intestine NENs), TGFÎ² and CTGF activate fibrogenic pathways resulting in local (peritoneal) or distant (cardiac) disease. The common activation of RAS/RAF signaling suggests that therapeutic agents that target elements of this pathway may be potentially effective in NENs.</div></div>